William P J Leenders

List of Publications by Year
in descending order

120 papers	4,501 citations	71102 41 h-index	118850 62 g-index
123 all docs	123 docs citations	123 times ranked	6530 citing authors

#	Article	IF	Citations
1	Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures. ACS Omega, 2022, 7, 3568-3578.	3.5	5
2	Targeted RNA next generation sequencing analysis of cervical smears can predict the presence of hrHPV-induced cervical lesions. BMC Medicine, 2022, 20, .	5.5	3
3	Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines. Cancers, 2021, 13, 1069.	3.7	5
4	Novel high-resolution targeted sequencing of the cervicovaginal microbiome. BMC Biology, 2021, 19, 267.	3.8	11
5	RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues. Modern Pathology, 2020, 33, 748-757.	5.5	11
6	p120-catenin-dependent collective brain infiltration by glioma cell networks. Nature Cell Biology, 2020, 22, 97-107.	10.3	79
7	EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer. Cancers, 2020, 12, 1762.	3.7	17
8	Monotherapy efficacy of bloodâ€“brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. Brain Communications, 2020, 2, fcaa002.	3.3	28
9	Isocitrate dehydrogenase 1â€“mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress. FASEB Journal, 2019, 33, 557-571.	0.5	33
10	Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer & Metabolism, 2019, 7, 4.	5.0	18
11	Molecular Profiling of Druggable Targets in Clear Cell Renal Cell Carcinoma Through Targeted RNA Sequencing. Frontiers in Oncology, 2019, 9, 117.	2.8	17
12	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers, 2019, 11, 2028.	3.7	23
13	Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing. Acta Neuropathologica Communications, 2019, 7, 185.	5.2	7
14	ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker. Cancers, 2019, 11, 1971.	3.7	21
15	The Importance of Wall Apposition in Flow Diverters. Neurosurgery, 2019, 84, 804-810.	1.1	32
16	The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, 63-72.	4.3	32
17	Effects of the Green Tea Polyphenol Epigallocatechin-3-Gallate on Glioma: A Critical Evaluation of the Literature. Nutrition and Cancer, 2018, 70, 317-333.	2.0	30
18	Flow diverter implantation in a rat model of sidewall aneurysm: a feasibility study. Journal of NeuroInterventional Surgery, 2018, 10, 88-92.	3.3	9

#	Article	IF	Citations
19	GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas. Journal of Experimental and Clinical Cancer Research, 2018, 37, 271.	8.6	22
20	Proteinaceous Regulators and Inhibitors of Protein Tyrosine Phosphatases. Molecules, 2018, 23, 395.	3.8	21
21	Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes. Scientific Reports, 2018, 8, 7072.	3.3	13
22	IDH1â€mutated gliomas rely on anaplerosis of glutamate and lactate whereas IDH1 wildâ€type gliomas rely on glycolysis and acetate anaplerosis. FASEB Journal, 2018, 32, 677.8.	0.5	0
23	Targeting the extracellular matrix of ovarian cancer using functionalized, drug loaded lyophilisomes. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 113, 229-239.	4.3	26
24	Glioma: experimental models and reality. Acta Neuropathologica, 2017, 133, 263-282.	7.7	223
25	Self-Assembling VHH-Elastin-Like Peptides for Photodynamic Nanomedicine. Biomacromolecules, 2017, 18, 1302-1310.	5.4	41
26	Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. American Journal of Pathology, 2017, 187, 940-953.	3.8	80
27	Legomedicineâ€"A Versatile Chemo-Enzymatic Approach for the Preparation of Targeted Dual-Labeled Llama Antibodyâ€"Nanoparticle Conjugates. Bioconjugate Chemistry, 2017, 28, 539-548.	3.6	36
28	A Conjugate of an Antiâ€Epidermal Growth Factor Receptor (EGFR) VHH and a Cellâ€Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation. ChemBioChem, 2017, 18, 2390-2394.	2.6	22
29	Altered metabolic landscape in <scp>IDH</scp> â€mutant gliomasÂaffects phospholipid, energy, and oxidative stress pathways. EMBO Molecular Medicine, 2017, 9, 1681-1695.	6.9	111
30	Recapitulating in vivo-like plasticity of glioma cell invasion along blood vessels and in astrocyte-rich stroma. Histochemistry and Cell Biology, 2017, 148, 395-406.	1.7	70
31	Profiling of the metabolic transcriptome via single molecule molecular inversion probes. Scientific Reports, 2017, 7, 11402.	3.3	17
32	Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity. Molecular Cancer Research, 2017, 15, 1587-1597.	3.4	12
33	In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma. Oncotarget, 2017, 8, 49165-49177.	1.8	61
34	Abstract 431: IDH1-mutated gliomas rely on anaplerosis of glutamate and lactate whereas IDH1 wild-type gliomas rely on glycolysis and acetate anaplerosis. Cancer Research, 2017, 77, 431-431.	0.9	1
35	Abstract 2077: Selective MET kinase inhibition in MET-dependent glioma models. , 2017, , .		0
36	Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. Scientific Reports, 2016, 6, 30486.	3.3	11

#	Article	IF	Citations
37	Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma. Acta Neuropathologica Communications, 2016, 4, 96.	5.2	22
38	Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients. Annals of Surgical Oncology, 2016, 23, 2745-2752.	1.5	36
39	In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued. Oncotarget, 2016, 7, 71594-71607.	1.8	11
40	Plexins. , 2016, , 3624-3628.		0
41	Abstract LB-308: Effects of the IDH1 R132H mutation on redox status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation. , 2016, , .		0
42	Transgenic mouse models of Idh-mutated neural stem cells: an appropriate model for low grade glioma?. Translational Cancer Research, 2016, 5, S1400-S1403.	1.0	1
43	Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC. Neoplasia, 2015, 17, 215-224.	5.3	14
44	Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathologica, 2015, 130, 131-144.	7.7	43
45	Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Research, 2015, 75, 4790-4802.	0.9	127
46	IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma. Cancer Research, 2014, 74, 4898-4907.	0.9	78
47	Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments. Neoplasia, 2014, 16, 221-228.	5.3	18
48	Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 66-74.	7.4	39
49	Tyrosine Kinase Inhibitor Sorafenib Decreases ¹¹¹In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma. Journal of Nuclear Medicine, 2014, 55, 242-247.	5.0	31
50	Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas. Neuro-Oncology, 2014, 16, 1669-1670.	1.2	22
51	Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility. Oncotarget, 2014, 5, 8690-8702.	1.8	28
52	Plexins. , 2014, , 1-4.		0
53	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and Î±-KG. Acta Neuropathologica Communications, 2013, 1, 18.	5.2	54
54	Robotic injection of zebrafish embryos for high-throughput screening in disease models. Methods, 2013, 62, 246-254.	3.8	84

#	Article	IF	Citations
55	Expression and clinical relevance of MET and ALK in Ewing sarcomas. International Journal of Cancer, 2013, 133, 427-436.	5.1	48
56	Nanobody-Functionalized Polymersomes for Tumor-Vessel Targeting. Macromolecular Bioscience, 2013, 13, 938-945.	4.1	34
57	Multivoxel 1H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting. Neuro-Oncology, 2013, 15, 1615-1624.	1.2	27
58	Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2. PLoS ONE, 2013, 8, e58262.	2.5	70
59	Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. Anti-Cancer Drugs, 2012, 23, 161-172.	1.4	10
60	Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IXâ€specific chimeric monoclonal antibody cG250. BJU International, 2011, 107, 118-125.	2.5	20
61	Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production. Histopathology, 2011, 59, 562-564.	2.9	8
62	Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. Journal of Pathology, 2011, 223, 626-634.	4.5	26
63	Characterization of Tumor Vasculature in Mouse Brain by USPIO Contrast-Enhanced MRI. Methods in Molecular Biology, 2011, 771, 477-487.	0.9	7
64	Glial Brain Tumors: Antiangiogenic Therapy. , 2011, , 109-119.		0
65	Plexins. , 2011, , 2927-2930.		0
66	Isolation of targeting nanobodies against co-opted tumor vasculature. Laboratory Investigation, 2010, 90, 61-67.	3.7	13
67	¹¹¹In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib. Journal of Nuclear Medicine, 2010, 51, 1707-1715.	5.0	47
68	Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies. Clinical Cancer Research, 2010, 16, 3431-3441.	7.0	52
69	Vascular Endothelial Growth Factor and Semaphorin Induce Neuropilin-1 Endocytosis via Separate Pathways: Correction. Circulation Research, 2010, 107, .	4.5	0
70	Imaging of HIV-Associated Kaposi Sarcoma; F-18-FDG-PET/CT and In-111-Bevacizumabscintigraphy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 444-446.	2.1	15
71	Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters, 2010, 299, 1-10.	7.2	52
72	Abstract 4187: A rapid and robust transgenic high-grade glioma mouse model for therapy-intervention studies. , 2010, , .		0

#	Article	IF	Citations
73	Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies. BMC Cancer, 2009, 9, 297.	2.6	42
74	Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer, 2009, 9, 444.	2.6	166
75	Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. Journal of Pathology, 2009, 219, 287-293.	4.5	67
76	Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. European Journal of Cancer, 2009, 45, 3074-3080.	2.8	25
77	Vascular Endothelial Growth Factor in Systemic Capillary Leak Syndrome. American Journal of Medicine, 2009, 122, e5-e7.	1.5	57
78	Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of Cell- and Matrix-Associated VEGF-A Isoforms. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 195-200.	1.0	21
79	Magnetic resonance imagingâ€based detection of glial brain tumors in mice after antiangiogenic treatment. International Journal of Cancer, 2008, 122, 1981-1986.	5.1	51
80	Specific imaging of VEGFâ€A expression with radiolabeled antiâ€VEGF monoclonal antibody. International Journal of Cancer, 2008, 122, 2310-2314.	5.1	59
81	The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. British Journal of Cancer, 2008, 98, 1250-1257.	6.4	120
82	Phenotypic and Genotypic Characterization of Orthotopic Human Glioma Models and Its Relevance for the Study of Antiâ€glioma Therapy. Brain Pathology, 2008, 18, 423-433.	4.1	67
83	Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. European Journal of Cancer, 2008, 44, 1835-1840.	2.8	59
84	Semaphorin 3E Expression Correlates Inversely with Plexin D1 During Tumor Progression. American Journal of Pathology, 2008, 173, 1873-1881.	3.8	48
85	Vessel normalization by VEGF inhibition: a complex story. Cancer Biology and Therapy, 2008, 7, 1014-1016.	3.4	11
86	Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. British Journal of Cancer, 2008, 98, 1784-1789.	6.4	56
87	Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Molecular Cancer Therapeutics, 2008, 7, 71-78.	4.1	98
88	Vascular Endothelial Growth Factor and Semaphorin Induce Neuropilin-1 Endocytosis via Separate Pathways. Circulation Research, 2008, 103, e71-9.	4.5	102
89	Plexins. , 2008, , 2373-2375.		0
90	Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene, 2007, 26, 5808-5815.	5.9	47

#	Article	IF	Citations
91	Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. European Journal of Cancer, 2006, 42, 3294-3303.	2.8	59
92	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: Lessons from endothelial cell biology. European Journal of Cell Biology, 2006, 85, 61-68.	3.6	27
93	Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. International Journal of Cancer, 2006, 119, 2054-2062.	5.1	24
94	Contrast Enhanced Susceptibility Weighted Imaging (CE-SWI) of the Mouse Brain Using Ultrasmall Superparamagnetic Ironoxide Particles (USPIO). Zeitschrift Fur Medizinische Physik, 2006, 16, 269-274.	1.5	10
95	Sprouting angiogenesis versus co-option in tumor angiogenesis. , 2005, , 65-76.		7
96	Plexin D1 Expression Is Induced on Tumor Vasculature and Tumor Cells: A Novel Target for Diagnosis and Therapy?. Cancer Research, 2005, 65, 8317-8323.	0.9	63
97	Increased vascularization predicts favorable outcome in follicular lymphoma. Clinical Cancer Research, 2005, 11, 154-61.	7.0	43
98	Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option. Clinical Cancer Research, 2004, 10, 6222-6230.	7.0	213
99	Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI.. International Journal of Cancer, 2003, 105, 437-443.	5.1	62
100	Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Research, 2003, 63, 5408-13.	0.9	72
101	Vessel Co-Option: How Tumors Obtain Blood Supply in the Absence of Sprouting Angiogenesis. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 83-87.	1.7	142
102	PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis. Developmental Dynamics, 2002, 225, 336-343.	1.8	88
103	Targetting VEGF in anti-angiogenic and anti-tumour therapy: Where are we now?. International Journal of Experimental Pathology, 2002, 79, 339-346.	1.3	23
104	Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1. Laboratory Investigation, 2002, 82, 473-481.	3.7	18
105	Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Research, 2002, 62, 341-5.	0.9	128
106	In vivoactivities of mutants of vascular endothelial growth factor (VEGF) with differentialin vitroactivities. International Journal of Cancer, 2001, 91, 327-333.	5.1	3
107	In vivo activities of mutants of vascular endothelial growth factor (VEGF) with differential in vitro activities. International Journal of Cancer, 2001, 91, 327-333.	5.1	10
108	Mutants of Basic Fibroblast Growth Factor Identify Different Cellular Response Programs. Growth Factors, 1997, 14, 213-228.	1.7	6

#	Article	IF	Citations
109	Synergism between temporally distinct growth factors: bFGF, insulin and lens cell differentiation. Mechanisms of Development, 1997, 67, 193-201.	1.7	41
110	Species specificity for HBsAg binding protein endonexin II. Journal of Hepatology, 1996, 24, 265-270.	3.7	5
111	Hepatitus B virus: specific binding and internalization of small HBsAg by human hepatocytes. Journal of General Virology, 1995, 76, 1047-1050.	2.9	8
112	Hepatitis Î´ virus attaches to human hepatocytes via human liver endonexin II, a specific HBsAg binding protein. Journal of Viral Hepatitis, 1994, 1, 33-38.	2.0	4
113	Cloning and Production of Functional Active Recombinant Hepatitis B Virus Surface Antigen Binding Protein. Biochemical and Biophysical Research Communications, 1994, 205, 52-59.	2.1	0
114	In vitro binding properties of the hepatitis delta antigens to the hepatitis B virus envelope proteins: potential significance for the formation of delta particles. Virus Research, 1994, 31, 27-37.	2.2	15
115	Spontaneous development of anti-hepatitis B virus envelope (anti-idiotypic) antibodies in animals immunized with human liver endonexin II or with the F(ab')2 fragment of anti-human liver endonexin II immunoglobulin G: evidence for a receptor-ligand-like relationship between small hepatitis B surface antigen and endonexin II. Journal of Virology, 1994, 68, 1516-1521.	3.4	19
116	Endonexin II, Present on Human Liver Plasma Membranes, Is a Specific Binding Protein of Small Hepatitis B Virus (HBV) Envelope Protein. Virology, 1993, 197, 549-557.	2.4	79
117	Host and tissue tropism of hepatitis B virus. Liver, 1992, 12, 51-55.	0.1	7
118	The role of PreS1 in the interaction of hepatitis B virus with human hepatocytes. Hepatology, 1991, 14, 405-406.	7.3	6
119	Binding of the major and large HBsAg to human hepatocytes and liver plasma membranes: Putative external and internal receptors for infection and secretion of hepatitis B virus. Hepatology, 1990, 12, 141-147.	7.3	34
120	Pulmonary Lymphangitis Carcinomatosis of Clear Cell Renal Cell Carcinoma After Angiogenesis Inhibition. Annals of Case Reports, 0, , .	0.0	1